Latest news with #ANDA
Business Upturn
13 hours ago
- Business
- Business Upturn
Nuvama bullish on Aurobindo Pharma, sees 15% profit CAGR through FY27
By Markets Desk Published on June 20, 2025, 07:30 IST Nuvama Institutional Equities has reiterated a 'Buy' call on Aurobindo Pharma, with a target price of ₹1,460, as it sees the stock poised for a strong recovery led by new product launches, capacity expansions, and normalization of regulatory and operational issues. The brokerage notes that Aurobindo has invested over ₹10,000 crore in recent years toward growth-oriented assets including its Pen-G API facility, injectable plants, and biologics and peptide capabilities. While these investments have temporarily diluted return ratios, Nuvama believes they position the company strongly for medium- to long-term growth, especially in high-margin, non-oral dosage categories. Key triggers that could unlock value in FY26–27 include: Resumption of production at its Pen-G unit , which could improve vertical integration and cost competitiveness. New launches in Europe from the company's Chinese facility. Ramp-up of injectables business through the Eugia-5 plant and normalization of supply issues from Eugia-3. Volume growth in oral solids, which continue to be the company's bread and butter in regulated markets like the US. Nuvama is building in a revenue CAGR of 7%, EBITDA CAGR of 8%, and PAT CAGR of 15% over FY25–27. Despite the recent recovery in pharma stocks, Aurobindo continues to trade at 13.9x FY27E EPS, which represents a 16% discount to its 5-year historical average valuation. This makes the stock attractive not only from a growth and margin recovery standpoint but also on relative valuation terms, especially considering that many of its operational headwinds now appear to be easing. Aurobindo has also stepped up its focus on specialty and complex generics, including biosimilars, peptides, and depot injections, which can provide earnings durability beyond FY27. The company's recent USFDA approvals and steady ANDA filings also indicate improving regulatory momentum. Nuvama's thesis remains that execution of these strategic pivots—especially monetization of recent capex—could drive a meaningful re-rating of the stock over the next 6–8 quarters. Ahmedabad Plane Crash Markets Desk at
Business Upturn
07-06-2025
- Business
- Business Upturn
Lupin gets U.S. FDA tentative approval for Generic Oxcarbazepine ER Tablets
Lupin Limited has announced that it has received tentative approval from the United States Food and Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) for Oxcarbazepine Extended-Release (ER) Tablets in 150 mg, 300 mg, and 600 mg strengths. These tablets are the generic equivalent of Oxtellar XR® ER Tablets by Supernus Pharmaceuticals and are indicated for the treatment of partial-onset seizures in patients aged 6 years and above. Lupin's version of the drug will be manufactured at its Nagpur facility in India. According to IQVIA MAT April 2025 data, Oxcarbazepine ER Tablets (RLD Oxtellar XR®) recorded estimated annual sales of USD 206 million in the United States, underscoring the potential market opportunity for Lupin. Headquartered in Mumbai, Lupin is a leading global pharmaceutical company with a strong footprint in the U.S. and India. The company focuses on a broad range of therapy areas including central nervous system disorders, respiratory, cardiovascular, anti-infective, and women's health. It operates 15 manufacturing sites and 7 research centers globally, supported by over 23,000 employees. Lupin continues to expand its U.S. portfolio of complex generics and remains committed to delivering high-quality, affordable medicines that improve health outcomes for patients around the world. Aman Shukla is a post-graduate in mass communication . A media enthusiast who has a strong hold on communication ,content writing and copy writing. Aman is currently working as journalist at
&w=3840&q=100)
Business Standard
04-06-2025
- Business
- Business Standard
Gland Pharma share rises 2% in trade on Wednesday, June 4; here's why
Gland Pharma share price: Pharmaceutical company Gland Pharma shares increased as much as 1.58 per cent to hit an intraday high of 1,619 per share on Wednesday, June 4, 2025. At 11:10 AM, Gland Pharma shares continued to trade near day's high, up 1.33 per cent at 1615 per share. Why did Gland Pharma share price rise? Gland Pharma shares rose after it secured United States Food and Drug Administration (USFDA) approval for its Abbreviated New Drug Application (ANDA) for Angiotensin II Acetate Injection 2.5 mg/mL. 'Gland Pharma Limited (Gland or Company), a generic injectable & ophthalmicfocused pharmaceutical company, has received approval from the United States Food and Drug Administration (USFDA) for its Abbreviated New Drug Application for Angiotensin II Acetate Injection 2.5 mg/mL,' Gland Pharma said, in a press release. Angiotensin II is a vasoconstrictor indicated for increasing blood pressure in adults with septic or other distributive shock. The Product is bioequivalent and therapeutically equivalent to the reference listed drug (RLD), Giapreza of La Jolla Pharma LLC, the company revealed. 'Gland Pharma is the exclusive First-to-File and is eligible for 180 days of generic drug exclusivity,' the company claimed. The product had US sales of approximately $58 million for the twelve months ending March 2025, according to IQVIA. Gland Pharma Q4 results Gland Pharma reported a 3 per cent year-on-year (YoY) decline in its consolidated net profit to ₹186.5 crore for the fourth quarter ended March 2025 (Q4FY25), compared to ₹192.4 crore in the same period last year. Revenue from operations fell 7 per cent YoY to ₹1,424.9 crore from ₹1,537.5 crore. The company's Ebitda stood at ₹347.5 crore, marginally down from ₹358.7 crore a year ago. However, the Ebitda margin improved to 24 per cent in Q4FY25, compared to 23 per cent in the corresponding quarter last year. Research and development (R&D) expenses during the quarter were ₹50.3 crore, accounting for 4.9 per cent of revenue. For the full financial year FY25, R&D expenses stood at ₹192.2 crore, or 4.7 per cent of annual revenue. Gland Pharma dividend About Gland Pharma Founded in 1978 in Hyderabad, Gland Pharma has evolved from a contract manufacturer of small-volume liquid parenterals to one of the largest injectable-focused pharmaceutical companies globally. Operating predominantly under a B2B model, it has a presence in over 60 countries, including the US, Europe, Canada, Australia, and India. The company's portfolio spans a wide range of sterile injectables such as vials, ampoules, pre-filled syringes, lyophilized vials, dry powders, infusions, as well as oncology and ophthalmic products. Notably, it pioneered Heparin technology in India.
Business Standard
04-06-2025
- Business
- Business Standard
Gland Pharma gets US FDA approval for hypotension treatment drug Angiotensin II
Gland Pharma said that it has received approval from the United States Food and Drug Administration (US FDA) for its abbreviated new drug application (ANDA) for Angiotensin II Acetate Injection. The product is bioequivalent and therapeutically equivalent to the reference listed drug (RLD) GIAPREZA of La Jolla Pharma LLC. This product is indicated for increasing the blood pressure in adults with septic or other distributive shock. Gland Pharma is the exclusive first-to-file and is eligible for 180 days of generic drug exclusivity. According to IQVIA, the product had US sales of approximately $58 million for the twelve months ending March 2025. Gland Pharma is one of the largest and fastest-growing injectable-focused companies, with a global footprint across 60 countries, including the United States, Europe, Canada, Australia, India, and other markets. It has a wide range of injectables, including vials, ampoules, pre-filled syringes, lyophilized vials, dry powders, infusions, oncology, and ophthalmic solutions. The company also pioneered heparin technology in India. The company's consolidated net profit declined 3.06% to Rs 186.54 crore as net sales fell by 7.32% to Rs 1424.91 crore in Q4 FY25 as compared with Q4 FY24. The scrip rose 0.32% to currently trade at Rs 1598.95 on the BSE.
Business Upturn
04-06-2025
- Business
- Business Upturn
Gland Pharma gets USFDA nod for Angiotensin II Acetate Injection, secures 180-day exclusivity
By Markets Desk Published on June 4, 2025, 08:20 IST Gland Pharma Limited has received final approval from the United States Food and Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) for Angiotensin II Acetate Injection, 2.5 mg/mL. The injectable product is bioequivalent and therapeutically equivalent to the reference listed drug GIAPREZA®, developed by La Jolla Pharma LLC. It is indicated for increasing blood pressure in adults suffering from septic or other distributive shock. Importantly, Gland Pharma is the exclusive First-to-File applicant for this product and has secured 180 days of generic drug exclusivity in the U.S. market. According to IQVIA data, US sales of Angiotensin II Acetate Injection stood at approximately USD 58 million for the twelve months ending March 2025, highlighting the commercial opportunity for Gland Pharma. This approval further strengthens Gland Pharma's injectables portfolio and underscores its regulatory and filing capabilities in complex products. Markets Desk at
